In a phase I study, HCC patients who progressed on prior therapy received a single infusion of C-CAR031, a GPC3-targeting CAR-T cell therapy that co-express a dominant negative TGF-b receptor II.537 The objective response rate was 50% in this small cohort of 22 patients. The gene discussed is GPC3; the disease is hepatocellular carcinoma.